StockNews.AI

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

StockNews.AI • 13 hours

ABMDSNN
High Materiality8/10

Information

ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a glob...

Original source

AI Summary

Axogen expects Q4 2025 revenue to be $59.9 million, up 21.3%. Full-year 2025 revenue projected at $225.2 million, a 20.2% increase. Gross margin is expected to exceed 74%, despite one-time FDA costs. Avance® received FDA BLA approval on December 3, 2025. Company aims to make nerve repair a standard in healthcare.

Sentiment Rationale

The revenue growth and FDA approval suggest strong future financial performance. Similar stock movements historically occur after positive earnings and FDA approvals.

Trading Thesis

Sustained revenue growth and market establishment will likely influence future stock performance positively.

Market-Moving

  • Axogen expects Q4 2025 revenue to be $59.9 million, up 21.3%.
  • Full-year 2025 revenue projected at $225.2 million, a 20.2% increase.
  • Gross margin is expected to exceed 74%, despite one-time FDA costs.

Key Facts

  • Axogen expects Q4 2025 revenue to be $59.9 million, up 21.3%.
  • Full-year 2025 revenue projected at $225.2 million, a 20.2% increase.
  • Gross margin is expected to exceed 74%, despite one-time FDA costs.
  • Avance® received FDA BLA approval on December 3, 2025.
  • Company aims to make nerve repair a standard in healthcare.

Companies Mentioned

  • ABMD (ABMD)
  • SNN (SNN)

Corporate Developments

The article highlights significant revenue milestones and regulatory approvals directly impacting market perception.

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

ALACHUA, Fla. and TAMPA, Fla., January 12, 2026 – Axogen, Inc. (NASDAQ: AXGN), a leader in developing innovative surgical solutions for peripheral nerve repair, has announced preliminary fourth quarter and full-year 2025 financial results.

Fourth Quarter and Year-End Financial Highlights

Axogen's revenue for the fourth quarter of 2025 is projected to reach approximately $59.9 million, marking a 21.3% increase compared to the fourth quarter of 2024. The expected revenue for the entire year 2025 is around $225.2 million, reflecting a robust 20.2% growth from 2024.

This growth is attributed to several factors, including:

  • Targeting high-potential accounts in Extremities and OMF-Head & Neck.
  • Expanding the use of Axogen’s comprehensive peripheral nerve surgical algorithm across various procedures.
  • Enhancing the market penetration of Resensation® in post-mastectomy breast reconstruction.

Moreover, the anticipated gross margin for both the fourth quarter and full year is expected to exceed 74%. One-time costs related to the FDA approval of Avance® are anticipated to amount to approximately $1.9 million, representing 3% for the fourth quarter and 1% for the full year.

Financial Position and BLA Approval

As of December 31, 2025, Axogen's balance of cash, cash equivalents, and investments is anticipated to be about $45.5 million, a rise of $6.0 million from the previous year end.

Significantly, on December 3, 2025, the FDA granted approval for the Biologics License Application (BLA) of Avance® (acellular nerve allograft-arwx), further propelling Axogen’s strategy for growth.

Company Executives Comment on Results

Michael Dale, President and Chief Executive Officer of Axogen, expressed enthusiasm regarding the company's achievements: “We are delighted with our preliminary fourth quarter and full year 2025 results. Our strong revenue growth and notable BLA milestone achievement during the quarter further validate our strategic plan and market development strategies.”

Dale emphasized Axogen's mission: “The approval of Avance® as a biologic therapeutic option for peripheral nerve discontinuities, combined with our positive momentum, gives us confidence that our mission to restore health and improve quality of life is progressing as planned.”

Outlook and Reporting Schedule

The results mentioned are preliminary and unaudited. Axogen plans to share comprehensive financial results for the fourth quarter and full year on late February 2026.

About Axogen

Axogen (NASDAQ: AXGN) specializes in the development and commercialization of advanced technologies for peripheral nerve repair. The company's goal is to establish nerve repair as the standard of care. Axogen’s portfolio includes:

  • Avance® (acellular nerve allograft-arwx)
  • Axoguard Nerve Connector®
  • Axoguard Nerve Protector®
  • Axoguard HA+ Nerve Protector™
  • Axoguard Nerve Cap®
  • Avive+ Soft Tissue Matrix™

These products are accessible across multiple countries, including the United States, Canada, Germany, the United Kingdom, and Spain.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains forward-looking statements defined under the Private Securities Litigation Reform Act of 1995. These statements reflect management's expectations concerning future conditions and outcomes based on various assumptions. Actual results may differ due to several factors, including supply chain disruptions, market awareness, and product adoption rates.

Related News